TAKEDA PHARMACEUTICAL COMPANY LIMITED
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1781-06-12
- Employees
- 10K
- Market Cap
- -
- Website
- https://www.takeda.no
Clinical Trials
429
Active:29
Completed:228
Trial Phases
5 Phases
Phase 1:52
Phase 2:48
Phase 3:118
+2 more phases
Drug Approvals
44
NMPA:41
SFDA:3
Drug Approvals
Leuprorelin Acetate Microspheres for Injection
- Product Name
- 抑那通/Enantone
- Approval Number
- 国药准字HJ20150326
- Approval Date
- Oct 29, 2024
NMPA
Leuprorelin Acetate Microspheres for Injection
- Product Name
- 抑那通
- Approval Number
- 国药准字HJ20150327
- Approval Date
- Oct 29, 2024
NMPA
Leuprorelin Acetate Microspheres for Injection
- Product Name
- 抑那通
- Approval Number
- 国药准字HJ20150329
- Approval Date
- Oct 29, 2024
NMPA
Leuprorelin Acetate Microspheres for Injection
- Product Name
- 抑那通
- Approval Number
- 国药准字HJ20150328
- Approval Date
- Oct 29, 2024
NMPA
Leuprorelin Acetate Microspheres for Injection
- Product Name
- 注射用醋酸亮丙瑞林微球
- Approval Number
- 国药准字HJ20150229
- Approval Date
- Aug 6, 2024
NMPA
Leuprorelin Acetate Microspheres for Injection
- Product Name
- 注射用醋酸亮丙瑞林微球
- Approval Number
- 国药准字HJ20150230
- Approval Date
- Aug 6, 2024
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
Clinical Trials
Distribution across different clinical trial phases (340 trials with phase data)• Click on a phase to view related trials
Phase 3
118 (34.7%)Not Applicable
96 (28.2%)Phase 1
52 (15.3%)Phase 2
48 (14.1%)Phase 4
14 (4.1%)phase_2_3
7 (2.1%)phase_1_2
5 (1.5%)No trials found
News
Neurocrine Biosciences Advances Osavampator into Phase 3 for Major Depressive Disorder
Neurocrine Biosciences has initiated a Phase 3 trial for osavampator as an adjunctive treatment for major depressive disorder (MDD).
Vietnam Launches Nationwide Dengue Fever Vaccination Program with Qdenga
Vietnam has initiated a nationwide dengue fever vaccination program, the first of its kind in the country, targeting individuals aged four and above.
European Regulators Recommend Cabometyx for Radioactive Iodine-Refractory Thyroid Cancer Based on 78% Reduction in Disease Progression
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cabometyx (cabozantinib) for treating radioactive iodine-refractory differentiated thyroid cancer patients who have progressed after prior systemic therapy.